Patents Issued in April 25, 2019
-
Publication number: 20190119362Abstract: A method for producing a protein includes adsorbing a protein including a ? chain variable region on an insoluble carrier of an affinity separation matrix by contacting a liquid sample including the protein with the affinity separation matrix; washing the affinity separation matrix to remove impurities; separating the protein from the affinity separation matrix by using an acidic buffer; and regenerating the affinity separation matrix by using an alkaline aqueous solution after the protein is separated from the affinity separation matrix. The insoluble carrier includes a ligand immobilized on the insoluble carrier, and the ligand is a ? chain variable region-binding peptide including B5 domain of Protein L derived from Peptostreptococcus magnus 312 strain or a variant of the B5 domain. The adsorbing, the washing, and the separating are repeated 3 or more times.Type: ApplicationFiled: October 31, 2018Publication date: April 25, 2019Applicant: KANEKA CORPORATIONInventors: Shinichi Yoshida, Dai Murata
-
Publication number: 20190119363Abstract: The invention provides chiral haptens (?)-3?-AmNic and (?)-N4N for use in generating antibodies in a patient specific for (?)-nicotine. The haptens can be conjugated to suitable carrier proteins and administered as an antigenic mixture, optionally comprising adjuvant(s), to a patient suffering from nicotine or tobacco addiction or habituation.Type: ApplicationFiled: December 10, 2018Publication date: April 25, 2019Inventors: Kim D. Janda, Jonathan W. Lockner
-
Publication number: 20190119364Abstract: The present invention includes a method of treating and/or preventing metabolic syndrome in a subject in need thereof. In certain embodiments, the method comprises administering to the subject a therapeutically effective amount of a composition that inhibits HDAC11 expression and/or activity, or induces HDAC11 degradation, in the subject.Type: ApplicationFiled: April 28, 2017Publication date: April 25, 2019Inventors: TIMOTHY A. MCKINSEY, RUSHITA BAGCHI, BRADLEY S. FERGUSON, MATTHEW S. STRATTON
-
Publication number: 20190119365Abstract: Humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide are provided. Methods of using antibodies specific to the protofibrillar form of the beta-amyloid peptide in the field of Alzheimer's disease are also provided.Type: ApplicationFiled: September 26, 2018Publication date: April 25, 2019Inventors: Nicolas Baurin, Francis Blanche, Beatrice Cameron, Marc Duchesne, Vincent Mikol, Souad Naimi, Laurent Pradier, Yi Shi
-
Publication number: 20190119366Abstract: Breast cancer cells lacking ER protein expression, PgR protein expression and/or showing absence of HER2 protein over-expression (i.e., triple-negative breast cancer cells, basal-like) can be efficiently targeted with an anti-KAAG1 antibody and killed upon delivery of a therapeutic moiety. Antibodies and antigen binding fragments that specifically binds to KAAG1 may thus be used for the, detection and therapeutic treatment of breast cancer cells that are negative for at least one of these markers. The use of antibody conjugates in the treatment of triple-negative breast cancer and/or basal-like breast cancer is disclosed herein.Type: ApplicationFiled: October 18, 2018Publication date: April 25, 2019Inventors: Gilles Bernard TREMBLAY, Anna N. MORAITIS, Mario FILION
-
Publication number: 20190119367Abstract: Disclosed herein is a method for identifying TREM-1's ligand and antibodies, or fragments thereof, which are capable of modifying the function of TREM-1's ligand. Antibodies that reduce or block TREM-1 activation may be identified and selected using this method. Antibodies that bind to TREM-1's ligand and reduce TREM-1 activity may be suitable for use as medicaments.Type: ApplicationFiled: October 25, 2018Publication date: April 25, 2019Applicant: Novo Nordisk A/SInventors: Vibeke Westphal STENNICKE, Christine Brender READ, Joseph Leon KUIJPER, Xiaoting TANG, Mark HEIPEL, Siv Annegrethe HJORTH
-
Publication number: 20190119368Abstract: This invention is in the field of treating or preventing inflammation in humans and animals and relates to pharmaceutical compositions and methods for treating or preventing various inflammatory conditions. In particular, the invention relates to compositions and methods for treating or preventing inflammatory conditions such as citrulline-related inflammatory diseases. The invention provides specific binding molecules directed against citrulline-containing epitopes for use in the therapy and prevention of inflammatory conditions.Type: ApplicationFiled: December 20, 2018Publication date: April 25, 2019Inventors: Jozef Maria Hendrik Raats, Renato Gerardus Silvano Chirivi
-
Publication number: 20190119369Abstract: The present disclosure provides a method of treating a nonalcoholic fatty liver disease in a subject, the method comprising administering to the subject a compound that inhibits VEGF-B signalling.Type: ApplicationFiled: April 21, 2017Publication date: April 25, 2019Inventors: Annika MEHLEM, Ulf ERIKSSON, Annelie FALKEVALL, Isolde PALOMBO
-
Publication number: 20190119370Abstract: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.Type: ApplicationFiled: August 23, 2018Publication date: April 25, 2019Inventors: Nancy Elizabeth Stagliano, James William West, Kathryn Kamath, Paul Henry Bessette, Fred Gluck, Jason Gary Sagert, Patrick Daugherty
-
Publication number: 20190119371Abstract: A method of treating a neurodegenerative disorder or MD comprises administering to a subject a composition comprising an AGE antibody.Type: ApplicationFiled: April 14, 2017Publication date: April 25, 2019Inventor: Lewis S. Gruber
-
Publication number: 20190119372Abstract: Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.Type: ApplicationFiled: December 20, 2018Publication date: April 25, 2019Inventors: Yue Yao, Janine M. Bilsborough
-
Publication number: 20190119373Abstract: The invention relates to antibodies directed against human Leukemia Inhibitory Factor (LIF) and to a hybridoma cell line producing said antibodies. The invention also relates to a method for blocking/inhibiting the proliferation of stem cells, and to an in vitro method for the diagnosis of diseases associated with unwanted cell proliferation in a subject or for determining the predisposition of a subject to suffer from said disease associated with unwanted cell proliferation, or for prognosis of average life expectancy of a subject suffering from said disease. The therapeutic potential of said antibodies is based on observing that the inhibition of LIF can be used in therapeutic compositions for the treatment of diseases associated with unwanted proliferation.Type: ApplicationFiled: May 14, 2018Publication date: April 25, 2019Applicants: FUNDACIO PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÒGICA VALL D'HEBRON (VHIO), FUNDACIO PRIVADA INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS (ICREA)Inventors: Joan Seoane Suarez, Judit Anido Folgueira, Andrea Saez Borderias
-
Publication number: 20190119374Abstract: Compositions and methods for minimizing antibody disulfide bond reduction are described. In one aspect, a composition is provided for culturing mammalian host cells to express an antibody including an anti-reduction agent that minimizes reduction of a disulfide bond in the antibody or fragment thereof. In some other aspects, methods for minimizing disulfide bond reduction; increasing production of an antibody or fragment thereof with intact native disulfide bonds; increasing a ratio of non-reduced to reduced antibody or fragment thereof; producing a therapeutic antibody or fragment thereof by adding a sufficient amount of an anti-reduction agent to a cell culture media, pre-harvest cell culture fluid, or harvest cell culture fluid are described. In another aspect, minimizing disulfide bond reduction in an antibody or fragment thereof culturing the host cell in a concentration of at least about 20% O2 is described.Type: ApplicationFiled: May 16, 2018Publication date: April 25, 2019Inventor: Sven Loebrich
-
Publication number: 20190119375Abstract: This application discloses anti-P-cadherin antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.Type: ApplicationFiled: May 24, 2018Publication date: April 25, 2019Applicant: Novartis AGInventors: Tinya Abrams, Steven Bruce Cohen, Jason Damiano, Clemens Dürr, Thomas Huber, Daniel Menezes, Kathy Miller, Katherine Rendahl, Jean-Michel Rene Rondeau
-
Publication number: 20190119376Abstract: The invention provides anti-TIGIT (T-cell immunoreceptor with Ig and ITIM domains) antibodies and methods of using the same.Type: ApplicationFiled: May 31, 2018Publication date: April 25, 2019Inventors: Jane L. GROGAN, Robert J. JOHNSTON, Yan WU, Wei-Ching LIANG, Patrick LUPARDUS, Mahesh YADAV, Dhaya SESHASAYEE, Meredith HAZEN
-
Publication number: 20190119377Abstract: This disclosure provides recombinant IgG Fc multimers and methods of treating autoimmune and inflammatory diseases by administering such multimers.Type: ApplicationFiled: January 27, 2017Publication date: April 25, 2019Inventors: Rolf SPIRIG, Fabian KAESERMANN, Adrian ZUERCHER, Con PANOUSIS, Adriana BAZ MORELLI, Chao-Guang CHEN
-
Publication number: 20190119378Abstract: This invention provides a humanized, anti-human receptor for advance glycation end-products (RAGE) monoclonal antibody or a fragment of such antibody which binds human RAGE as well as compositions containing, and uses of, such antibody and fragments.Type: ApplicationFiled: April 11, 2017Publication date: April 25, 2019Applicant: The Trustees of Columbia University in the City of New YorkInventors: Yared Tekabe, Lynne Johnson
-
Publication number: 20190119379Abstract: Embodiments of the disclosure concern treatment of cancer utilizing methods and compositions that block CD47 such that tumor associated macrophages (TAMs) are not inhibited by CD47 and are able to phagocytose and kill tumor cells. In specific embodiments, the compositions and their use concern fusions of an entity that binds CD47 and an entity that binds cells having FC receptors, such as the FC receptor on TAMs. Certain embodiments concern gene therapy that produces a fusion of the ectodomain of SIRPa and the constant region of IgG4 at a localized tumor or tumor microenvironment, for example. In specific cases, gene transfer is utilized to deliver SIRPa fusion genes into a tumor and/or tumor microenvironment so that the molecules can be expressed locally to increase efficacy (given that the expression of the molecules will be highest at tumor sites) and decrease potential toxicities.Type: ApplicationFiled: April 18, 2017Publication date: April 25, 2019Inventors: Stephen M. G. Gottschalk, Felicia Cao
-
Publication number: 20190119380Abstract: The disclosure provides a method for treating or preventing a disease or disorder associated with lung inflammation by inhibiting the conversion of type 2 innate lymphoid cells (ILC2s) to type 1 innate lymphoid cells (ILC1s).Type: ApplicationFiled: April 19, 2017Publication date: April 25, 2019Inventors: ALISON A. HUMBLES, JONATHAN S. SILVER, ROLAND KOLBECK
-
Publication number: 20190119381Abstract: The present invention relates to binding compounds specific for BTLA and uses thereof. More specifically, the invention relates to fully human antibodies that recognize human BTLA and modulate its activity in cancer, inflammatory, and autoimmune disorders.Type: ApplicationFiled: October 31, 2018Publication date: April 25, 2019Inventors: Jennifer Marie MATARAZA, Andrea Van ELSAS, Alan J. KORMAN, Edward L. HALK, Kent B. THUDIUM, Mark J. SELBY, Timothy W. SPROUL, Heidi N. LEBLANC
-
Publication number: 20190119382Abstract: The invention is directed to a bispecific chimeric antigen receptor, comprising: (a) at least two antigen-specific targeting regions; (b) an extracellular spacer domain; (c) a transmembrane domain; (d) at least one co-stimulatory domain; and (e) an intracellular signaling domain, wherein each antigen-specific targeting region comprises an antigen-specific single chain Fv (scFv) fragment, and binds a different antigen, and wherein the bispecific chimeric antigen receptor is co-expressed with a therapeutic control. The invention also provides methods and uses of the bispecific chimeric antigen receptors.Type: ApplicationFiled: January 4, 2019Publication date: April 25, 2019Applicant: Seattle Children's Hospital d/b/a Seattle Children's Research InstituteInventor: Michael Jensen
-
Publication number: 20190119383Abstract: The present invention generally relates to novel protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides. The present invention also relates to polynucleotides encoding such protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides of the invention, and to methods of using these protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides in the treatment of disease.Type: ApplicationFiled: September 21, 2018Publication date: April 25, 2019Inventors: Peter BRUENKER, Rebecca CROASDALE-WOOD, Christian KLEIN, Juergen Michael SCHANZER, Kay-Gunnar STUBENRAUCH, Pablo UMANA, Martina GEIGER, Eric SULLIVAN, Jigar PATEL
-
Publication number: 20190119384Abstract: The presently subject matter provides novel human sequence antibodies against human CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies.Type: ApplicationFiled: December 26, 2018Publication date: April 25, 2019Inventors: Alan J. Korman, Edward L. Halk, Nils Lonberg, Yashwant M. Deo, Tibor P. Keler
-
Publication number: 20190119385Abstract: CAR cells targeting and antibodies human HLA-G are described as a new method of cancer treatment. It is proposed that HLA-G CAR cells are safe and effective in patients and can be used to treat human tumors expressing the HLA-G.Type: ApplicationFiled: March 25, 2016Publication date: April 25, 2019Applicant: University of Southern CaliforniaInventors: Alan L. Epstein, Peisheng Hu
-
Publication number: 20190119386Abstract: Methods for inhibiting degeneration of a neuron, methods of treating a neurological/neurodegenerative disease, methods of modulating the directional growth of a neuron, and methods of interfering with the interaction of Wnt and Ryk are provided herein. Also provided are isolated anti-Ryk antibodies and antibody fragments that specifically bind to a binding domain of Wnt.Type: ApplicationFiled: March 28, 2017Publication date: April 25, 2019Inventor: Yimin Zou
-
Publication number: 20190119387Abstract: The invention relates to improved compositions and methods for treating diseases, such as cancer, by providing a combination therapy comprising a TGF? Receptor (TGF?R) antagonist comprising a domain antibody and a cell immunotherapy, in particular where the cell immunotherapy is an immunomodulatory cell expressing a chimeric antigen receptor (CAR) or a modified T cell receptor (TCR). The invention further relates to polynucleotides, expression vectors and immunomodulatory cells comprising the combination therapy, as well as methods of generating said immunomodulatory cells.Type: ApplicationFiled: April 5, 2017Publication date: April 25, 2019Inventor: Sara Jane BRETT
-
Publication number: 20190119388Abstract: The present invention provides a pharmaceutical composition for inhibiting the metastasis of cancer, comprising, as an active ingredient, an antibody that specifically binds to an epidermal growth factor receptor, and a method for inhibiting the metastasis of cancer using the composition. The composition or the method is effective in inhibiting the invasion of various gastric cancer cell lines induced by EGFR ligands. Therefore, the pharmaceutical composition can be usefully used for inhibiting the metastasis of cancer.Type: ApplicationFiled: April 27, 2016Publication date: April 25, 2019Applicants: GREEN CROSS CORPORATION, MOGAM INSTITUTE FOR BIOMEDICAL RESEARCHInventors: Jong-hwa WON, Yangmi LIM, Min-Kyu HUR
-
Publication number: 20190119389Abstract: Provided herein are antigen-binding proteins (ABPs) that selectively bind to NRP-1 and its isoforms and homologs, and compositions comprising the ABPs. Also provided are methods of using the ABPs, such as therapeutic and diagnostic methods.Type: ApplicationFiled: January 3, 2019Publication date: April 25, 2019Inventors: Daniel Hicklin, Cynthia Seidel-Dugan, William Winston, Jose-Andres Salmeron-Garcia, Nels P. Nielson, Heather Brodkin
-
Publication number: 20190119390Abstract: Methods of treating pigmented villonodular synovitis (PVNS) with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided.Type: ApplicationFiled: June 22, 2018Publication date: April 25, 2019Applicant: Five Prime Therapeutics, Inc.Inventors: Robert Sikorski, Julie Hambleton, Nilacantan Sankar
-
Publication number: 20190119391Abstract: The present disclosure provides anti-CXCR3 antibodies and methods of using the antibodies to diagnose and/or treat CXCR3-associated disorders such as diabetes mellitus type I (T1D), particularly new-onset T1D. In certain embodiments, disclosed herein are CXCR3 neutralizing antibodies.Type: ApplicationFiled: September 14, 2018Publication date: April 25, 2019Inventors: Michele Youd, Jennifer Tedstone, Tracey Lodie, Karen B. Carter, Timothy D. Connors, Jason Robert Pinckney, Elizabeth Masterjohn, Ruiyin Chu
-
Publication number: 20190119392Abstract: Methods are provided for the treatment of IL-6R related diseases. More specifically, specific dose regimens and pre-filled syringes are provided for subcutaneous administration, to subjects suffering an IL-6R related disease, of immunoglobulin single variable domains that bind IL-6R.Type: ApplicationFiled: September 27, 2018Publication date: April 25, 2019Applicant: Ablynx N.V.Inventors: Sven Hoefman, Maria-Laura Sargentini-Maier, Katrien Van Beneden
-
Publication number: 20190119393Abstract: Polypeptides are provided directed against IL-6R at specific dose ranges and dosing schedules that result in a prolonged effect on IL-6 mediated signaling. In particular, the invention provides pharmacologically active agents, compositions, methods and/or dosing schedules that have certain advantages compared to the agents, compositions, methods and/or dosing schedules that are currently used and/or known in the art, including the ability to dose less frequently or to administer lower doses to obtain equivalent effects in inhibiting IL-6 mediated signaling.Type: ApplicationFiled: October 2, 2018Publication date: April 25, 2019Applicant: Ablynx N.V.Inventors: Josefin-Beate Holz, Stefaan Rossenu, Steven De Bruyn, Maria-Laura Sargentini-Maier, Özkan Yalkinoglu
-
Publication number: 20190119394Abstract: Death receptor 5 (DR5) agonist compositions and methods for treating pancreatitis have been developed. The compositions include Tumor Necrosis Factor-related apoptosis-inducing ligand (TRAIL), its analogues, and anti-DR5 agonistic antibodies. In certain embodiments, TRAIL analogs and anti-death receptor 5 agonistic antibodies have analgesic and disease modifying effects on the pancreas.Type: ApplicationFiled: April 7, 2017Publication date: April 25, 2019Applicant: The Johns Hopkins UniversityInventors: Seulki Lee, Martin G. Pomper, Ogyi Park, Magdalena Scully, Pankaj J. Pasricha
-
Publication number: 20190119395Abstract: This disclosure provides combination therapy for treating a subject, such as a subject afflicted with a lung cancer, comprising administering to the subject an anti-fucosyl-GM1 antibody and an anti-CD137 antibody, or antigen-binding portions of either or both.Type: ApplicationFiled: April 14, 2017Publication date: April 25, 2019Inventors: Josephine M. CARDARELLI, Daniel E. LOPES de MENEZES, Paul D. PONATH, Bingliang CHEN, Chin PAN
-
Publication number: 20190119396Abstract: Anti-SIRP? antibodies, including multi-specific anti-SIRP? antibodies, are provided, as are related compositions and methods. The antibodies of the disclosure bind to SIRP? and can block the interaction of CD47 on one cell with SIRP? on a phagocytic cell.Type: ApplicationFiled: July 25, 2018Publication date: April 25, 2019Inventors: Jie Liu, Jens-Peter Volkmer
-
Publication number: 20190119397Abstract: Aspects of the disclosure provide compositions and methods for treating cancer characterized by surface expression of plectin-1. In some embodiments, the disclosure provides anti-plectin-1 antibodies. In some embodiments, the anti-plectin-1 antibodies are conjugated to a targeted moiety (e.g., a therapeutic moiety or a detectable label).Type: ApplicationFiled: April 7, 2017Publication date: April 25, 2019Applicant: iTi Health, Inc. d/b/a ZielBioInventors: Kimberly A. Kelly, Julien Dimastromatteo
-
Publication number: 20190119398Abstract: Provided are survivin specific antibodies, nucleic acids encoding the antibodies and methods for treating tumors comprising survivin-expressing cells by administration of the antibodies. The antibody compositions were found to be effective in inhibiting the growth of tumors.Type: ApplicationFiled: December 27, 2018Publication date: April 25, 2019Inventors: Robert A. Fenstermaker, Michael J. Ciesielski
-
Publication number: 20190119399Abstract: Provided herein are therapeutic polypeptides, e.g., chimeric antigen receptors, able to direct an immune cell, e.g., a T lymphocyte to a target antigen, and able to cause the T cell to proliferate or to kill cells displaying the antigen when the antigen binds to the polypeptide, wherein the polypeptides comprise a transmembrane domain from a T cell co-inhibitory protein such as CTLA4 or PD-1. Also provided herein are T lymphocytes expressing the polypeptides, and use of such T lymphocytes to treat diseases such as cancer.Type: ApplicationFiled: October 30, 2018Publication date: April 25, 2019Applicant: CELGENE CORPORATIONInventors: Stewart Abbot, Bitao Liang, Tianjian Li
-
Publication number: 20190119400Abstract: The present disclosure relates to anti-glyco-MUC1 antibodies and antigen binding fragments thereof that specifically bind to a cancer-specific glycosylation variant of MUC1 and related fusion proteins and antibody-drug conjugates, as well as nucleic acids encoding such biomolecules. The present disclosure further relates to use of the antibodies, antigen-binding fragments, fusion proteins, antibody-drug conjugates and nucleic acids for cancer therapy.Type: ApplicationFiled: October 23, 2018Publication date: April 25, 2019Applicant: GO Therapeutics, Inc.Inventor: Thayer WHITE
-
Publication number: 20190119401Abstract: Provided are methods of suppressing growth of triple negative breast tumors and basal-like breast tumors by contacting tumor cells with an ErbB3 inhibitor, e.g., an anti-ErbB3 antibody. Also provided are methods for treating triple negative breast cancer or basal-like breast cancer in a patient by administering to the patient an ErbB3 inhibitor, e.g., an anti-ErbB3 antibody. The treatment methods can further comprise selecting a patient having a triple negative breast cancer or basal-like breast cancer and then administering an ErbB3 inhibitor to the patient. The treatment methods also can further comprise administering at least one additional anti-cancer agent to the patient in combination with the ErbB3 inhibitor.Type: ApplicationFiled: May 31, 2018Publication date: April 25, 2019Inventors: Victor MOYO, Gabriela GARCIA
-
Publication number: 20190119402Abstract: The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.Type: ApplicationFiled: July 13, 2018Publication date: April 25, 2019Inventors: Thomas Dudler, Wayne R. Gombotz, James Brian Parent, Clark E. Tedford, Anita Kavlie, Urs Beat Hagemann, Herald Reiersen, Sergej Kiprijanov
-
Publication number: 20190119403Abstract: Cathepsin B plays a crucial role in promoting cancer cells invasion and metastasis. Through structure-guided rational design, Applicants have generated monoclonal antibodies specifically inhibiting human cathepsin B proteolytic activity. These novel antibody inhibitors provide potential potent anti-metastasis therapeutics with excellent safety profiles.Type: ApplicationFiled: March 31, 2017Publication date: April 25, 2019Inventors: Yong Zhang, Zhefu Dai
-
Publication number: 20190119404Abstract: Provided herein is a proprotein convertase subtilisin kexin type 9 (PCSK9)-specific binding protein that comprises unique complementary determining regions, that is capable of specifically binding to PCSK9, effectively inhibiting the function of PCSK9, lowering plasma LDL cholesterol level and that is useful in treating diseases associated with or impacted by the function of PCSK9.Type: ApplicationFiled: April 7, 2017Publication date: April 25, 2019Applicant: MAB-SCIENCE (HONG KONG) LIMITEDInventor: Shaoxiong Wang
-
Publication number: 20190119405Abstract: Described herein are methods and compositions relating to anti-Chi3L1 antibodies, antibody reagents, and antigen-binding fragments thereof which display superior properties, e.g., high sensitivity, high specificity, high binding affinity, neutralization activity ex vivo and in vivo (e.g., blocks Chi3L1-induced MAPK and AKT signaling). Methods of treatment, e.g., of treating cancer, obesity, and/or asthma by administering the compounds described herein are also provided.Type: ApplicationFiled: December 21, 2018Publication date: April 25, 2019Applicant: BROWN UNIVERSITYInventors: Jack A. Elias, Chun Geun Lee, Chuan Hua He, Bing Ma, Suchitra Kamle, Chang-Min Lee
-
Publication number: 20190119406Abstract: Novel multispecific antibody platform, multispecific antibodies and a method to make the antibodies is disclosed here. The CH3 domain harboring polypeptide chains of the Fc-regions are modified by increasing the positive charge of one chain and negative charge of another chain. Heterodimer formation in cotransfection with the modified chains is comparable to formation of wild type antibodies when same cell line is transfected with wild type polypeptides. Moreover, the modification provides a simple one step purification of the heterodimers.Type: ApplicationFiled: August 3, 2016Publication date: April 25, 2019Applicant: BISON THERAPEUTICS INC.Inventor: Wenjun ZHANG
-
Publication number: 20190119407Abstract: The present invention concerns antigen binding proteins that bind TL1A, including bispecific antigen binding proteins (e.g., antibodies) to TL1A and TNF-?. Such bispecific antibodies can be in a tetrameric immunoglobulin format, in which one heavy chain-light chain pair of the antibody is directed to TL1A and the other to TNF-?. The bispecific antigen binding proteins may also be comprised in an IgG-scFv fusion, in which a conventional tetrameric antibody directed to one antigen is fused to a pair of single chain Fv units directed to the other. The bispecific antigen binding protein may also be comprised in an IgG-Fab fusion, in which a Fab molecule that binds to one antigen is fused to each heavy chain of a conventional tetrameric antibody directed to the other antigen. The invention further relates to uses of the anti-TL1A binding proteins and anti-TL1A/anti-TNF-? antigen binding proteins, and pharmaceutical formulations thereof.Type: ApplicationFiled: December 14, 2016Publication date: April 25, 2019Applicant: AMGEN INC.Inventors: Hailing HSU, Gunasekaran KANNAN, Kenneth W. WALKER, Michelle HORTTER, Edward J. BELOUSKI
-
Publication number: 20190119408Abstract: This invention provides a method for producing a polyrotaxane, the method being capable of producing a polyrotaxane in a high yield within a short period of time, using a small number of steps. The method for producing the polyrotaxane of the present invention is a method for producing a polyrotaxane having a structure in which a linear molecule passes through openings of cyclic molecules, the method comprising the step of heating a starting material containing the linear molecule and the cyclic molecule to the melting temperature of the linear molecule or higher, to obtain a clathrate compound of the linear molecule and the cyclic molecule.Type: ApplicationFiled: April 27, 2017Publication date: April 25, 2019Inventors: Akira Harada, Yoshinori Takashima, Shunji Kohri, Masaki Nakahata
-
Publication number: 20190119409Abstract: The present invention relates to a modified polymer having the structure of Formula (I) and Formula (IV): wherein A, R1, R2, R3, a, and n are as described herein and wherein R, R?, R?, x, and k are as described herein and methods for preparation thereof. The present invention also relates to a compound having the structure of Formula (II): wherein A, R1, R2, R3, a, and n are as described herein. The present invention also relates to a process for polymerizing unsaturated hydrocarbon monomers.Type: ApplicationFiled: October 22, 2018Publication date: April 25, 2019Inventors: Aaron David Sadow, Bradley M. Schmidt, Gwanghoon Kwag, Hanbaek Lee, Dong Eun Kang
-
Publication number: 20190119410Abstract: The present invention is concerned with a reactive surfactant composition for emulsion polymerization, which is able to micronize the particle diameter of a polymer emulsion and to reduce the addition amount of the reactive surfactant composition to be used. The reactive surfactant composition for emulsion polymerization of the present invention contains a reactive anionic surfactant (component A) represented by the following formula (I), the component A being satisfied with the following requirement R: wherein AO represents an alkyleneoxy group having a carbon number of 3 or more and 18 or less; EO represents an ethyleneoxy group; p represents an integer of 1 or more and 15 or less; m? represents an integer of 0 or more; n? represents an integer of 0 or more; W represents a hydrogen ion or a cation; and plural kinds of AOs may coexist.Type: ApplicationFiled: October 3, 2016Publication date: April 25, 2019Applicant: KAO CORPORATIONInventors: Shogo KAMENOUE, Takayuki IKENAGA, Atsuhito MORI
-
Publication number: 20190119411Abstract: Residual hydrogenation catalyst produced from reduction of nitrile rubber is recovered by a chelation step using a chelating agent and a series of extraction using semi-coagulation with polar solvents and an optional washing steps for the separation of catalyst-chelating agent complex from hydrogenated nitrile rubber solution. The chelating agent is selected from xanthate, dithiocarbamate, and trithiocarbonate compounds.Type: ApplicationFiled: December 19, 2018Publication date: April 25, 2019Inventors: Soobum Choi, Lawrence J. Justice, Mahesh Datla, Mike Recchio